Schedule 13G ownership disclosure

Vistagen Therapeutics Inc

Common Stock · CUSIP: 92840H400

Event date: 2025-12-31

Filing-level shares
1,824,738
Percent of class
4.62%
  • The Vanguard Group

    Shares: 1,824,738 · Class: 4.62%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000102909-26-000313
Form type
SCHEDULE 13G/A
Filer
VANGUARD GROUP INC
CIK
CIK 102909
Filed
Jan 30, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub